GlioPharma ApS
APSDissolvedAdvertising protectionCVR 37256641Birkemose Allé 27, 6000 KoldingAnden forskning og eksperimentel udvikling inden for naturvidenskab og teknik· NACE 721900Est. 2015 · 10 years old— employees
Loading company…
Overview
GlioPharma ApS is a Danish APS based in Kolding, operating in the Anden forskning og eksperimentel udvikling inden for naturvidenskab og teknik sector. Incorporated in 2015, the company reported a gross profit of -DKK 14.5k in its latest annual filing.
Gross profit 2018
-14.5K DKK
−218% vs 2017
EBITDA margin (of gross profit)
100.0 %
−218% vs 2017
Net profit 2018
-21.6K DKK
-589% vs 2017
Key ratios
See full ratios →Solidity ratioEquity ÷ Total assets × 100
19.5 %
WeakAmong the 30% lowest rated companies in the industry
20172018
Liquidity ratioCurrent assets ÷ Short-term debt
1.2×
WeakAmong the 40% lowest rated companies in the industry
20172018
Return on assets (ROA)Net profit ÷ Total assets × 100
-12.8 %
WeakAmong the 30% lowest rated companies in the industry
20172018
EBITDA — year on year
DKK thousandsKey figures
Annual report 2018| Gross profit | -14.5K DKK | -218% |
| EBITDA | -14.5K DKK | -218% |
| Net profit | -21.6K DKK | -589% |
| Total assets | 168.7K DKK | -8% |
| Equity | 32.8K DKK | -40% |
| Employees | — | — |
Company information
Legal name
GlioPharma ApS
CVR number
37256641
Legal form
Anpartsselskab
Founded
25 November 2015 · 10 years
Share capital
DKK 50,000
Employees
—
VAT registered
No
Audit selected
No
Last report
2018-04-30
Financial year
January – December
Signatory rights
Selskabet tegnes af den samlede direktion.
Contact
Address
Birkemose Allé 27, 6000 Kolding
Advertising protection
Active — opted out of marketing use
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
Financial development
In its most recent annual report (2018), GlioPharma ApS reported a gross profit of -DKK 14.5k, a decrease of 218% on the year before. The figures on this page draw on 2 annual filings covering 2017 to 2018. The bottom line showed a net loss of DKK 21.6k.
At the end of 2018, equity financed 19.5% of the balance sheet, and current assets covered short-term debt 1.2 times.
Financials
Gross profit
DKK thousandsEBITDA
DKK thousandsIncome statement
DKK thousands| Item | 2018 | 2017 |
|---|---|---|
| Gross profit | -15 | 12 |
| Staff expenses | -0 | -0 |
| EBITDA | -15 | 12 |
| Depreciation & amort. | -0 | -0 |
| EBIT | -15 | 12 |
| Net financials | -7 | -5 |
| Profit before tax | -22 | 7 |
| Tax | -0 | 3 |
| Net profit | -22 | 4 |
Get a credit rating – not just the numbers
Financial statements show the past. Risika gives you a score and a recommended credit limit, so you know what the numbers mean for your risk.
Balance sheet
DKK thousands| Item | 2018 | 2017 |
|---|---|---|
| Total assets | 169 | 184 |
| Equity | 33 | 54 |
| Long-term debt | 0 | 104 |
| Short-term debt | 136 | 26 |
| Total debt | 136 | 130 |
Financial ratios
5-year trendEBITDA margin (of gross profit)
<−999 %
20172018
Equity ratio
19.5 %
WeakAmong the 30% lowest rated companies in the industry
20172018
Return on equity
-65.8 %
Very weakAmong the 10% lowest rated companies in the industry
20172018
Net profit margin (of gross profit)
<−999 %
20172018
Asset turnover (of gross profit)
-0.09×
20172018
Debt / equity
4.14×
Very weakAmong the 10% lowest rated companies in the industry
20172018
Sector performance
22 of 28 ratios graded28 financial ratios from the latest filing, each graded against companies in the same industry.
Profitability
Return on equity (ROE)Very weak
Among the 10% lowest rated companies in the industry
Net profit as a percentage of equity — the return the owners earned on their invested capital this year.
Return on assets (ROA)Weak
Among the 30% lowest rated companies in the industry
Net profit as a percentage of total assets — the return generated on the capital employed.
Return on net assets (RONA)Very weak
Among the 10% lowest rated companies in the industry
Profit relative to net assets (total assets minus total debt) — the ability to generate earnings from the net asset base alone.
Basic earning power (BEP)Weak
Among the 30% lowest rated companies in the industry
EBIT relative to total assets — the company's earning power before the effects of tax and financial leverage.
Gross marginNot rated
Cannot be graded — the figures this ratio builds on are not available in the latest filing.
The gross result as a share of revenue — how much of the revenue is left after variable costs to cover the company's fixed costs.
Operating marginNot rated
Cannot be graded — the figures this ratio builds on are not available in the latest filing.
EBIT as a share of revenue — the share of revenue remaining as earnings once all operating costs are covered. A key measure of earning power.
Net profit marginNot rated
Cannot be graded — the figures this ratio builds on are not available in the latest filing.
The profit for the year as a share of revenue — the company's ability to turn revenue into profit.
Capacity ratioNot rated
Cannot be graded — the figures this ratio builds on are not available in the latest filing.
Shows how strongly fixed costs weigh on the gross result — a high ratio means fixed costs take only a small bite out of the earnings from basic operations.
Liquidity
Current ratioWeak
Among the 40% lowest rated companies in the industry
Current assets relative to short-term debt — the ability to settle short-term obligations with current assets alone. Around 150% is considered satisfactory from a credit perspective.
Quick ratioWeak
Among the 40% lowest rated companies in the industry
Current assets excluding inventory relative to short-term debt — whether the most liquid assets alone can cover the short-term obligations. A value of 1 or above signals a healthy liquidity position.
Cash ratioStrong
Among the 40% highest rated companies in the industry
Cash relative to short-term debt — the ability to repay short-term obligations with cash alone.
Current assets to equityVery weak
Among the 10% lowest rated companies in the industry
Current assets relative to equity — an indicator of the balance-sheet structure and of the company's short- and long-term financing. The healthy level is highly industry-dependent.
Fixed assets to long-term capitalVery strong
Among the 10% highest rated companies in the industry
Fixed assets relative to long-term capital (equity plus long-term liabilities). Below 100% means the long-term capital finances more than just the fixed assets — a healthier liquidity position.
Cash conversion ratioWeak
Among the 30% lowest rated companies in the industry
Cash flow relative to profit — the ability to convert reported profits into accessible cash.
Debt & solvency
Solidity ratioWeak
Among the 30% lowest rated companies in the industry
Equity as a share of total assets — the ability to absorb losses. Around 40% is considered satisfactory from a credit perspective.
Debt ratioWeak
Among the 30% lowest rated companies in the industry
Total debt relative to the balance-sheet total — the share of the assets financed by debt rather than equity.
Debt to equityVery weak
Among the 10% lowest rated companies in the industry
Debt relative to equity — the company's leverage. A higher value means heavier reliance on debt financing.
Liabilities to equityVery weak
Among the 10% lowest rated companies in the industry
Total liabilities relative to equity — whether the company operates primarily on borrowed capital or on its own.
Income to debtWeak
Among the 30% lowest rated companies in the industry
Profit relative to debt — the ability to create earnings while operating with debt.
EBITDA to debtWeak
Among the 30% lowest rated companies in the industry
EBITDA relative to debt — how much operating earnings are available to service the debt.
Interest coverageWeak
Among the 30% lowest rated companies in the industry
The ability to pay the interest on the company's debt out of its earnings.
Interest rate on debtWeak
Among the 30% lowest rated companies in the industry
Financial expenses relative to total liabilities — the effective interest rate the company pays on its debt.
Interest marginWeak
Among the 30% lowest rated companies in the industry
The return on assets minus the interest rate on debt. Positive means the company benefits from operating with debt; negative means the debt makes it worse off.
Efficiency & development
Equity to contributed capitalWeak
Among the 30% lowest rated companies in the industry
Total equity relative to the capital the owners contributed — how the equity has developed from its starting point.
One-year change in equityVery weak
Among the 20% lowest rated companies in the industry
The size of this year's increase or decrease in the company's equity.
One-year change in debtAverage
Around the average of companies in the same industry
The size of this year's increase or decrease in the company's debt.
Asset turnoverNot rated
Cannot be graded — the figures this ratio builds on are not available in the latest filing.
Revenue relative to total assets — the ability to generate revenue from the asset base.
Inventory turnoverNot rated
Cannot be graded — the figures this ratio builds on are not available in the latest filing.
Revenue relative to inventory — how many times a year the inventory is sold and replaced. A low value can indicate weak sales or excess inventory.
Annual reports & filings
People & ownership
Management
Actively employed in the business| Name | Role | Member since |
|---|
Former (1)
JB Chief Executive Officer | Chief Executive Officer | 2015 – 2019 |
Board of directors
Non-executive oversight| Name | Role | Member since |
|---|
Former (1)
JB Chairman | Chairman | 2015 – 2018 |
Shareholders
Active legal owners| Shareholder | Type | Ownership | Votes | Registered |
|---|---|---|---|---|
| Individual | 33.33–49.99% | 33.33–49.99% | 2015 | |
| Individual | 33.33–49.99% | 33.33–49.99% | 2015 | |
| Company | 33.33–49.99% | 33.33–49.99% | 2015 | |
| Company | 10–14.99% | 10–14.99% | 2015 | |
| Company | 33.33–49.99% | 33.33–49.99% | 2015 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
One in three Danish companies experiences fraud
Sound familiar? See how to strengthen your defences and catch suspicious changes in ownership and management in time.
Related companies
Company hierarchy
DK INVEST AF 19.12.2011 ApS
GlioPharma ApS (this company)Board network connections
Board members of GlioPharma ApS also hold positions in 3 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Jette Bjerrum | Chief Executive Officer | 2 companies |
| John Bo Jacobsen | Chairman | 1 company |
Frequently asked questions
What is the CVR number of GlioPharma ApS?
GlioPharma ApS is registered with CVR / Virk under CVR 37256641.
What is the gross profit of GlioPharma ApS?
GlioPharma ApS reported a gross profit of -DKK 14.5k in 2018.
Where is GlioPharma ApS headquartered?
GlioPharma ApS's registered address is Birkemose Allé 27, 1..